Genocea Biosciences (NASDAQ:GNCA) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Genocea Biosciences (NASDAQ:GNCAGet Rating) in a research note issued to investors on Monday. The brokerage issued a sell rating on the biotechnology company’s stock.

Genocea Biosciences Price Performance

GNCA stock opened at $0.02 on Monday. The company has a market capitalization of $880,950.00, a P/E ratio of -0.02 and a beta of 1.52. The company has a debt-to-equity ratio of 0.24, a quick ratio of 1.35 and a current ratio of 1.35. Genocea Biosciences has a 52-week low of $0.00 and a 52-week high of $1.48. The business has a 50-day simple moving average of $0.01 and a two-hundred day simple moving average of $0.03.

About Genocea Biosciences

(Get Rating)

Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor.

See Also

Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.